Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Another target on the books
February 2019
SHARING OPTIONS:

INGELHEIM, Germany & CAMBRIDGE, Mass.—Under the auspices of its 2017 collaboration with Dicerna Pharmaceuticals, Boehringer Ingelheim has exercised its option to receive exclusive rights to a second hepatic disease target from the companies’ agreement. The partners are pursuing the discovery and development of novel GalXC RNAi therapeutics for the treatment of chronic liver diseases, and initially are focusing their efforts on nonalcoholic steatohepatitis (NASH). Per the collaboration and license agreement, with the execution of this option, Boehringer Ingelheim will be responsible for future clinical development and commercialization of the target, while Dicerna is eligible for development and commercial milestone payments, as well as royalties on worldwide net sales.
 
“It is extremely gratifying for Boehringer Ingelheim to exercise its option for a second therapeutic candidate from our productive research collaboration,” Douglas M. Fambrough, president and CEO of Dicerna, said in a press release. “The option exercise underscores the potential of Dicerna’s GalXC technology platform in facilitating the discovery and development of novel RNAi therapies for nonalcoholic steatohepatitis and other chronic liver diseases. We look forward to continued progress and the potential advancement of clinical candidates from our partnership.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.